Cannabinoid, CB1 agonists in cervical dystonia: Failure in a phase IIa randomized controlled trial

Basal Ganglia

Volumn 1, Issue 2, 2011, Pages 91-95

  Zadikoff, C ^a,b   Wadia, P M ^a,c   Miyasaki, J ^a   Chen, R ^a   Lang, A E ^a   So, J ^a   Fox, S H ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b NORTHWESTERN UNIVERSITY   (United States)

^c JASLOK HOSPITAL AND RESEARCH CENTRE   (India)

Author keywords

Cannabinoids; Cervical dystonia; Dronabinol; Randomised controlled trial

Indexed keywords

CANNABINOID 1 RECEPTOR AGONIST; DRONABINOL; PLACEBO;

ADULT; AGED; ANXIETY; ARTICLE; BITTER TASTE; BLURRED VISION; CERVICAL DYSTONIA; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; INSOMNIA; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SHORT COURSE THERAPY; SIDE EFFECT; SOMNOLENCE; SYSTOLIC BLOOD PRESSURE; TORONTO WESTERN HOSPITAL SPASMODIC TORTICOLLIS RATING SCALE; VERTIGO; VISUAL ANALOG SCALE; WEIGHT CHANGE; XEROSTOMIA;

EID: 79960346734     PISSN: 22105336     EISSN: 22105336     Source Type: Journal    
DOI: 10.1016/j.baga.2011.04.002     Document Type: Article

References (38)

1. Nutt J.G., Muenter M.D., Melton L.J., Aronson A., Kurland L.T. Epidemiology of dystonia in Rochester, Minnesota. Adv Neurol 1988, 50:361-365.
2. Mejia N.I., Vuong K.D., Jankovic J. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 2005, 20:592-597.
3. Brotchie J.M. Advances in understanding the neural mechanisms underlying L-DOPA-induced dyskinesia. Adv Neurol 1999, 80:71-85.
4. Lozano A.M., Kumar R., Gross R.E., et al. Globus pallidus internus pallidotomy for generalized dystonia. Mov Disord 1997, 20:865-870.
5. Mitchell I.J., Luquin R., Boyce S., et al. Neural mechanisms of dystonia: evidence from a 2-deoxyglucose uptake study in a primate model of dopamine agonist-induced dystonia. Mov Disord 1990, 5:49-54.
6. Mitchel I.J., Boyce S., Sambrook M.A., Crossman A.R. A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia. Brain 1992, 115:809-824.
7. Matsumura M., Tremblay L., Richard H., Filion M. Activity of pallidal neurons in the monkey during dyskinesia induced by injection of bicuculline in the external pallidum. Neuroscience 1995, 65:59-70.
8. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 1990, 87:1932-1936.
9. Herkenham M., Lynn A.B., de Costa B.R., Richfield E.K. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res 1991, 547:267-274.
10. Glass M., Faull R.L., Dragunow M. Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. Neuroscience 1993, 56:523-527.
11. Wong D.F., Kuwabara H., Horti A.G., Raymont V., Brasic J., Guevara M. Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR. Neuroimage 2010, 52:1505-1513.
12. Pertwee R.G., Greentree S.G. Delta-9-tetrahydrocannabinol-induced catalepsy in mice is enhanced by pretreatment with flurazepam or chlordiazepoxide. Neuropharmacology 1988, 27:485-491.
13. Maneuf Y.P., Nash J.E., Crossman A.R., Brotchie J.M. Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduced gamma-aminobutyric acid uptake in teh globus pallidus. Eur J Pharmacol 1996, 308:161-164.
14. Venderova K., Brown T.M., Brotchie J.M. Differential effects of endocannabinoids on [(3)H]-GABA uptake in the rat globus pallidus. Exp Neurol 2005, 194:284-287.
15. Matyas F., Yanovsky Y., Mackie K., Kelsch W., Misgeld U., Freund T.F. Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia. Neuroscience 2006, 137:337-361.
16. Miller A.S., Walker J.M. Local effects of cannabinoids on spontaneous activity and evoked inhibition in the globus pallidus. Eur J Pharmacol 1998, 352:199-205.
17. Engler E., Freiman L., Urbanski M., Szabo B. Effects of exogenous and endogenous cannabinoids on GABAergic neurotransmission between the caudate-putamen and the globus pallidus in the mouse. J Pharmacol Exp Ther 2006, 316:608-617.
18. Richter A., Loscher W. (+)-WIN 55, 212-2, a novel cannabinoid receptor agonist, exerts antidystonic effects in mutant dystonic hamsters. Eur J Pharmacol 1994, 264:371-377.
19. Fox S.H., Henry B., Hill M., Crossman A., Brotchie J. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord 2002, 17:1180-1187.
20. Fox S.H., Kellett M., Moore A.P., Crossman A.R., Brotchie J.M. Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov Disord 2002, 17:145-149.
21. Sieradzan K.A., Fox S.H., Hill M., Dick J., Crossman A.R., Brotchie J.M. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 2001, 57:2108-2111.
22. Orr L.E., McKernan J.F. Antiemetic effect of delta 9-tetrahydrocannabinol in chemotherapy-associated nausea and emesis as compared to placebo and compazine. J Clin Pharmacol 1981, 21(Suppl. 8-9):76S-80S.
23. Devine M.L., Dow G.J., Greenberg B.R., et al. Adverse reactions to delta-9-tetrahydrocannabinol given as an antiemetic in a multicenter study. Clin Pharm 1987, 6:319-322.
24. Consky E.S., Lang A.E. Clinical assessments of patients with cervical dystonia. Therapy with Botulinum Toxin 1994, 211-238. Marcel Dekker, Inc., New York. J. Jankovic, M. Hallett (Eds.).
25. Comella C.L., Stebbins G.T., Goetz C.G., Chmura T.A., Bressman S.B., Lang A.E. Teaching tape for the motor section of the Toronto western spasmodic torticollis scale. Mov Disord 1997, 12:570-575.
26. Truong D., Duane D.D., Jankovic J., Singer C., Seeberger L.C., Comella C.L., et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord 2005, 20:783-791.
27. Consroe P., Sandyk R., Snider S.R. Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 1986, 30:277-282.
28. Resstel L.B., Tavares R.F., Lisboa S.F., Joca S.R., Corrêa F.M., Guimarães F.S. 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br J Pharmacol 2009, 156:181-188.
29. Pertwee R. Cannabinoids. Handbook of Experimental Pharmacology 2005, Springer Verlag, Heidelberg. R.G. Pertwee (Ed.).
30. Marinol A. Product Monograph. Solvay Pharma 2004.
31. Fox S.H. Cannabinoids. Encyclopedia of Movement Disorders, vol. 1 2010, Academic Press, Oxford, pp. 178-182. K. Kompoliti, L. Verhagen Metman (Eds.).
32. Jabusch H.C., Schneider U., Altenmuller E. Delta9-tetrahydrocannabinol improves motor control in a patient with musician's dystonia. Mov Disord 2004, 19:990-991.
33. Gauter B., Rukwied R., Konrad C. Cannabinoid agonists in the treatment of blepharospasm-a case report study. Neuro Endocrinol Lett 2004, 25:45-48.
34. Rog D.J., Nurmikko T.J., Friede T., Young C.A. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005, 65:812-819.
35. Pryce G., Baker D. Emerging properties of cannabinoid medicines in management of multiple sclerosis. Trends Neurosci 2005, 28:272-276.
36. Ware M., Beaulieu P. Cannabinoids for the treatment of pain: An update on recent clinical trials. Pain Res Manag 2005, 10:27A-30A.
37. Hall W., Solowij N. Adverse effects of cannabis. Lancet 1998, 352:1611-1616.
38. Zajicek J.P., Sanders H.P., Wright D.E., et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005, 76:1664-1669.